The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Novel Cathepsin K Inhibitor Promising for OA

Novel Cathepsin K Inhibitor Promising for OA

June 10, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although researchers have investigated cathepsin K inhibitors as potential treatments for osteoporosis, the development of many potential compounds has stopped due to its association with the increased frequency of morphea or stroke. A recent study found the novel cathepsin K inhibitor MIV-711 both significantly reduces bone and cartilage progression and has a reassuring safety profile. However, MIV-711 was no more effective than placebo for pain.

You Might Also Like
  • Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
  • TNF Inhibitor Drug Tapering Successful in Some Patients with RA
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
Also By This Author
  • EHRs Play a Role in Physician Burnout

The findings by Philip G. Conaghan, MBBS, PhD, professor of musculoskeletal medicine, Leeds University, U.K., and colleagues suggest MIV-711 should be investigated as a disease-modifying osteoarthritis (OA) drug. The investigators published their findings in the January 2020 issue of the Annals of Internal Medicine.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Study
The investigators screened 433 patients with primary knee OA and identified 244 who were on a stable analgesic regimen. Most participants were female (76.7%) and white (99.2%). The investigators randomly assigned patients to one of three groups: 100 mg/day of MIV-711, 200 mg/day of MIV-711 or placebo. Treatment adherence was 100% in all study groups. The primary outcome was pain improvement. Ultimately, although average pain severity in the target knee decreased in both treatment groups, the difference in pain after treatment was not statistically significant.

For the secondary outcome, the researchers evaluated 204 participants using extremely sensitive magnetic resonance imaging (MRI) techniques. They found statistically significant attenuation of femoral bone area progression, as well as a reduction of femoral cartilage thinning, in the active treatment groups compared with placebo. Specifically, they documented an attenuation of thinning of medial femoral joint cartilage of 0.066 mm in the MIV-711 groups compared with placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The study also included measures of the biomarkers type I collagen C-telopeptide (CTX-1) and CTX-II as predictors of OA progression. At week 26, the researchers documented significant changes in these bone and cartilage biomarker levels in both MIV-711 groups compared with placebo. When compared with baseline, levels of CTX-I (serum) and CTX-II (urine) were reduced by 27.8% and 34.4% in the 100 mg group and by 50.3% and 51.6% in the 200 mg group. Levels of both biomarkers returned to baseline values after treatment stopped at week 26.

The researchers report that treatment-emergent adverse events were similar across all groups: 55% for placebo, 54.9% for 100 mg/day and 52.4% for 200 mg/day. None of the adverse events were treatment related. Most of the events were mild (46.9%) or moderate (50.7%), and included nasopharyngitis, osteoarthritis and headache. Nine serious adverse events occurred in six participants: one in the placebo group, three in the 100 mg/day group and two in the 200 mg/day group. Serious adverse events included atrial fibrillation, acute cholecystitis, prinzmetal angina, compression fracture, confusion, cerebral infarction and hematoma. The investigators found no cases of morphea associated with MIV-711. There were also no clinically meaningful changes in vital signs, such as blood pressure, electrocardiographic assessments or key laboratory measures in the groups.

Pages: 1 2 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: cathepsin-K inhibitor, Knee Osteoarthritis (OA), Osteoarthritis, Pain

You Might Also Like:
  • Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
  • TNF Inhibitor Drug Tapering Successful in Some Patients with RA
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.